Kliogest

Norethisterone acetate and estradiol, the active ingredients in Kliogest, constitute a combined estrogen‑progestogen oral contraceptive formulated as an oral tablet for systemic administration. The preparation works by suppressing ovulation and modifying cervical mucus, providing reliable contraception for women of childbearing potential.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide under strict quality standards. All batches are manufactured in accordance with EU GMP guidelines and are exported under controlled conditions to meet global regulatory requirements.

Kliogest, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception.

- Prevention of pregnancy: provides reliable contraception for women of childbearing age. - Menstrual cycle regulation: helps maintain a predictable monthly bleeding pattern while using the contraceptive. - Reduction of functional ovarian cysts: suppresses ovulation, decreasing the incidence of ovarian cyst formation.

Kliogest may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Mood changes: irritability or depressive symptoms. - Spotting between periods: light vaginal bleeding. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty. - Hepatic adenoma: benign liver tumor.

Before prescribing Kliogest, clinicians should evaluate the following safety considerations. - Pregnancy contraindication: do not use in pregnant women. - Smoking restriction: avoid in women over 35 who smoke. - Cardiovascular risk: assess history of thromboembolic disease before use. - Liver disease: use with caution in patients with hepatic impairment. - Migraine with aura: contraindicated due to increased stroke risk. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Kliogest can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampicin, carbamazepine): markedly reduce hormone levels, decreasing contraceptive effectiveness. - Antiretrovirals (e.g., efavirenz): lower plasma concentrations, risking breakthrough ovulation. - Antifungal agents (e.g., ketoconazole): increase estrogen levels, potentially heightening side‑effect risk. - St. John’s Wort: accelerates hormone metabolism, compromising contraception. - Certain antibiotics (e.g., griseofulvin): may diminish contraceptive reliability.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs): may exacerbate mood changes. - Antihypertensives (beta‑blockers): possible alteration of blood pressure control. - Diuretics: may affect fluid balance and electrolyte status. - Herbal supplements (ginkgo): monitor for increased bleeding tendency. - Anticonvulsants (phenytoin): moderate reduction in contraceptive efficacy.